The Assessment and Efficiency of Cefixime in Upper Respiratory Tract Infections: Insights and Perspectives.
cefixime
clinical practice
insights
pediatrics
respiratory tract infections
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
accepted:
22
06
2024
medline:
15
8
2024
pubmed:
15
8
2024
entrez:
15
8
2024
Statut:
epublish
Résumé
Upper respiratory tract infections (URTIs) are common in patients of the pediatric age group and often lead to significant morbidity and mortality. Antibiotics such as cefixime have contributed to the management of URTIs, particularly when bacterial etiology is suspected. Several studies have evaluated the effectiveness of cefixime in pediatric URTIs, showing promising results in alleviating symptoms and reducing the duration of illness. Cefixime, a third-generation cephalosporin, exhibits broad-spectrum activity against common pathogens implicated in URTIs, including
Identifiants
pubmed: 39144897
doi: 10.7759/cureus.64539
pmc: PMC11322408
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e64539Informations de copyright
Copyright © 2024, Shafi et al.
Déclaration de conflit d'intérêts
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.